PARP1 and cancer: For this reason, PARP1 inhibitors, like olaparib, trapping PARP1 on the lesion owing to inactivation of its catalytic activity (80) as well as reversing allostery (30,81), are approved for use in the treatment of cancers with defective homologous recombination mechanisms (82).